Zolbetuximab
Brand names: Vyloy
Zolbetuximab is a monoclonal antibody given by intravenous infusion, used with chemotherapy for advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma that is CLDN18.2-positive and HER2-negative.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds the tight-junction protein claudin-18.2 on tumour cells and triggers immune-mediated cell killing through antibody-dependent cellular and complement-dependent cytotoxicity.
Prescribing in practice
- Severe nausea and vomiting are very common, especially with the first infusions, and require premedication including antiemetics with the infusion given at a controlled rate.
- CLDN18.2 positivity must be confirmed by a validated test before treatment.
- It is a specialist oncology medicine given under supervision experienced in infusion reactions.
Monitoring
Monitor for infusion-related reactions and gastrointestinal symptoms during and after each infusion, with antiemetic cover.
Counselling the patient
- Expect nausea and vomiting particularly with early infusions, and report if these are severe or persistent.
- Tell staff at once about infusion reactions such as flushing, breathlessness or chest tightness.
- Attend all infusion appointments as part of the combination regimen.
Evidence & guidelines
Efficacy in CLDN18.2-positive gastric cancer is supported by the SPOTLIGHT and GLOW phase 3 trials.
Reference: ESMO guidelines; SmPC (EMA approval 2024); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.